NVC-002

NVC-002 is a preclinical-stage genetic medicine being developed by Nuevocor. While the specific indication and mechanism of action for NVC-002 have not been publicly disclosed, it is part of Nuevocor’s pipeline of pathway-specific gene therapies targeting cardiomyopathies and other diseases with mechanobiological underpinnings. The company’s platform focuses on addressing disease pathways shared across multiple forms of cardiomyopathy, rather than targeting individual gene mutations as in traditional gene replacement therapy approaches[1]. As of June 2025, no detailed information about the molecular target, modality, or route of administration for NVC-002 has been released.

Brand names

NVC-002NVC002NVC 002

Other names

NVC-002NVC002NVC 002